Passive Prophylactic Administration with a Single Dose of Anti–Fel d 1 Monoclonal Antibodies REGN1908–1909 in Cat Allergen–induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial

Abstract

Rationale: Sensitization to Fel d 1 ( Felis domesticus allergen 1) contributes to persistent allergic rhinitis and asthma. Existing treatment options for cat allergy, including allergen immunotherapy, are only moderately effective, and allergen immunotherapy has limited use because of safety concerns. Objectives: To explore the relationship among the pharmacokinetic, clinical, and immunological effects of anti–Fel d 1 monoclonal antibodies (REGN1908–1909) in patients after treatment. Methods: Patients received REGN1908–1909 ( n = 36) or a placebo ( n = 37) in a phase 1b study. Fel d 1–induced basophil and IgE-facilitated allergen binding responses were evaluated at baseline and Days 8, 29, and 85. Cytokine and chemokine concentrations in nasal fluids were measured, and REGN1908–1909 inhibition of allergen–IgE binding in patient serum was evaluated. Measurements and Main Results: Peak serum drug concentrations were concordant with maximal observed clinical response. The anti–Fel d 1 IgE/cat dander IgE ratio in pretreatment serum correlated with Total Nasal Symptom Score improvement. The allergen-neutralizing capacity of REGN1908–1909 was observed in serum and nasal fluid and was detected in an inhibition assay. Type 2 cytokines (IL-4, IL-5, and IL-13) and chemokines (CCL17/TARC, CCL5/RANTES [regulated upon activation, normal T-cell expressed and secreted]) in nasal fluid were inhibited in REGN1908–1909–treated patients compared with placebo ( P < 0.05 for all); IL-13 and IL-5 concentrations correlated with Total Nasal Symptom Score improvement. Ex vivo assays demonstrated that REGN1908 and REGN1909 combined were more potent than each alone for inhibiting FcεRI- and FcεRII (CD23)–mediated allergic responses and subsequent T-cell activation. Conclusions: A single, passive-dose administration of Fel d 1–neutralizing IgG antibodies improved nasal symptoms in cat-allergic patients and was underscored by suppression of FcεRI-, FcεRII-, and T-helper cell type 2–mediated allergic responses. Clinical trial registered with www.clinicaltrials.gov (NCT02127801)

Targeting immunodominant Bet v 1 epitopes with monoclonal antibodies prevents the birch allergic response

“…current study, it is possible that these Bet v 1-specific mAbs will also inhibit allergen-IgE complex binding to low affinity receptors (FceRII/CD23) present on B cells, as demonstrated previously using Fel d 1 antibodies. 47 In addition to influencing cellular and humoral processes, treatment of a specific allergy may lower the overall ''allergic threshold.'' In the patient who is polyallergic, exposure to 1 offending allergen may not be enough to elicit symptoms; however, additive exposure to multiple allergens may exceed the patient's allergy threshold resulting in effector cell activation.…”

From Allergen Molecules to Molecular Immunotherapy of Nut Allergy: A Hard Nut to Crack

“…Besides complex alterations of the cellular and cytokine responses it has become clear that the induction of allergen-specific IgG and perhaps of allergen-specific IgA antibodies which block IgE binding to the allergen and accordingly the IgE antibody-mediate pathology is a key mechanism of AIT ( 234 – 236 ). This has been evidenced in clinical studies using molecular approaches for AIT ( 237 , 238 ) and by the demonstration that passive immunization with allergen-specific blocking IgG antibodies is clinically effective ( 239 – 241 ).…”

Allergen-specific IgG Antibodies for Cat Allergy?

“…The work by Shamji and colleagues (pp. 23–33 ) in this issue of the Journal ( 2 ), and the 2018 study by Orengo and colleagues ( 3 ), report successful AIT for cat allergy and potentially, if verified by larger trials, could lead to a major leap forward for AIT. Allergens used for cat allergy AIT, both sublingual and subcutaneous, have progressed from crude extracts to sophisticated and targeted allergens.…”